These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 35132410)
1. Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth. Ku Z; Xie X; Lin J; Gao P; El Sahili A; Su H; Liu Y; Ye X; Li X; Fan X; Goh BC; Xiong W; Boyd H; Muruato AE; Deng H; Xia H; Jing Z; Kalveram BK; Menachery VD; Zhang N; Lescar J; Shi PY; An Z bioRxiv; 2022 Feb; ():. PubMed ID: 35132410 [TBL] [Abstract][Full Text] [Related]
2. Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth. Ku Z; Xie X; Lin J; Gao P; Wu B; El Sahili A; Su H; Liu Y; Ye X; Tan EY; Li X; Fan X; Goh BC; Xiong W; Boyd H; Muruato AE; Deng H; Xia H; Zou J; Kalveram BK; Menachery VD; Zhang N; Lescar J; Shi PY; An Z Nat Commun; 2022 Sep; 13(1):5552. PubMed ID: 36138032 [TBL] [Abstract][Full Text] [Related]
3. An Engineered IgG-VHH Bispecific Antibody against SARS-CoV-2 and Its Variants. Chi H; Wang L; Liu C; Cheng X; Zheng H; Lv L; Tan Y; Zhang N; Zhao S; Wu M; Luo D; Qiu H; Feng R; Fu W; Zhang J; Xiong X; Zhang Y; Zu S; Chen Q; Ye Q; Yan X; Hu Y; Zhang Z; Yan R; Yin J; Lei P; Wang W; Lang G; Shao J; Deng Y; Wang X; Qin C Small Methods; 2022 Dec; 6(12):e2200932. PubMed ID: 36300882 [TBL] [Abstract][Full Text] [Related]
5. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290 [TBL] [Abstract][Full Text] [Related]
6. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299 [TBL] [Abstract][Full Text] [Related]
7. An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2. Sun C; Chi H; Yuan F; Li J; Yang J; Zheng A; Wang F; Sun L; Zhang Y; Hu P; Jiao L; Deng Y; Xie L Sci China Life Sci; 2023 Jan; 66(1):165-179. PubMed ID: 36184693 [TBL] [Abstract][Full Text] [Related]
8. Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant. Jia L; Liu YP; Tian LF; Xiong C; Xu X; Qu H; Xiong W; Zhou D; Wang F; Liu Z; Yan XX; Xu W; Tang L MedComm (2020); 2021 Sep; 2(3):442-452. PubMed ID: 34541573 [TBL] [Abstract][Full Text] [Related]
9. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses. Wang Y; Liu M; Shen Y; Ma Y; Li X; Zhang Y; Liu M; Yang XL; Chen J; Yan R; Luan D; Wang Y; Chen Y; Wang Q; Lin H; Li Y; Wu K; Zhu T; Zhao J; Lu H; Wen Y; Jiang S; Wu F; Zhou Q; Shi ZL; Huang J Cell Discov; 2022 Apr; 8(1):36. PubMed ID: 35443747 [TBL] [Abstract][Full Text] [Related]
10. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM Elife; 2022 Aug; 11():. PubMed ID: 36004719 [TBL] [Abstract][Full Text] [Related]
11. An engineered bispecific human monoclonal antibody against SARS-CoV-2. Li Z; Li S; Zhang G; Peng W; Chang Z; Zhang X; Fan Z; Chai Y; Wang F; Zhao X; Li D; Zhang R; He Z; Zou W; Xu K; Lei W; Liu P; Hao J; Zhang J; Sun L; Wu G; Tan S; Gao GF; Gao F; Wu Y Nat Immunol; 2022 Mar; 23(3):423-430. PubMed ID: 35228696 [TBL] [Abstract][Full Text] [Related]
12. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434 [TBL] [Abstract][Full Text] [Related]
13. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196 [TBL] [Abstract][Full Text] [Related]
14. IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2. Nikitin PA; DiMuzio JM; Dowling JP; Patel NB; Bingaman-Steele JL; Heimbach BC; Henriquez N; Nicolescu C; Polley A; Sikorski EL; Howanski RJ; Nath M; Shukla H; Scheaffer SM; Finn JP; Liang LF; Smith T; Storm N; McKay LGA; Johnson RI; Malsick LE; Honko AN; Griffiths A; Diamond MS; Sarma P; Geising DH; Morin MJ; Robinson MK Sci Immunol; 2022 Sep; 7(75):eabl9943. PubMed ID: 35771946 [TBL] [Abstract][Full Text] [Related]
15. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer. Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918 [TBL] [Abstract][Full Text] [Related]
16. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern. Akkız H Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924 [TBL] [Abstract][Full Text] [Related]
17. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants. Jeong BS; Cha JS; Hwang I; Kim U; Adolf-Bryfogle J; Coventry B; Cho HS; Kim KD; Oh BH MAbs; 2022; 14(1):2021601. PubMed ID: 35030983 [TBL] [Abstract][Full Text] [Related]
18. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration. Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535 [TBL] [Abstract][Full Text] [Related]